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It is  generally accepted that  T  cells produce lymphokines during  the generation 
and expression of ceil-mediated immunity (reviewed in  1). Lymphokine preparations 
often exhibit  antiviral  activity that  is known  to be mediated by interferon  (IFN)) 
This IFN, because of its distinct  antigenic and physicoehemical properties, has been 
designated IFNy to differentiate it from the IFNa and IFNfl classes (2).  In addition 
to its distinct molecular nature, IFNy has been reported to be relatively more active 
than other classes of IFN in its ability to directly inhibit the growth of neoplastic cells 
(3, 4) as well as in its ability to function as an immunomodulator (5, 6). Because of its 
T  cell origin and pronounced actions on immune responses, it is conceivable that the 
primary role of the lymphokine IFNy might be one other than its antiviral action. 
IFNy has been detected  in  sera of immunized mice after injection  of sensitizing 
antigen (7) or in vitro after exposure of lymphoid cells of immune animals to antigen 
(8,  9).  In place of specific antigenic stimulation, polyclonal T  cell mitogens such as 
phytohemagglutinin  (PHA)  or eoneanavalin A  (Con A)  have been used in  vitro to 
induce the synthesis of low levels of IFNy from lymphoid cells of nonimmune animals 
(10,  1 1). Because polyclonal mitogens stimulate a  far greater number of T  cells than 
does specific antigen, it was considered of interest to determine whether lymphocytes 
from animals actively expressing T  cell-mediated  immunity might  produce  higher 
IFNy levels in response to PHA or Con A. The studies presented in this paper show 
that  spleen  cells  from animals  given  an  immunizing  infection  with  the  bacterium 
Listeria  monocytogenes  consistently produced  10- to 20-fold more IFNy than cells from 
normal  mice  after  exposure  to  PHA  or  Con  A.  This  finding  has  enabled  the 
development  of a  reproducible  method  for the  production  of high-titered  murine 
IFNy (MulFNy). These studies also reveal a striking parallel between the development 
ofT cell-mediated anti-Listeria  immunity (12,  13)  and an enhanced ability of spleen 
cells  from  the  responding  mice  to  produce  IFNy  in  response  to  PHA  or  Con  A 
stimulation.  Some physicochemical properties of mitogen-induced MuIFNy are also 
presented. 
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Materials and Methods 
Animals.  Male and female AB6F1 mice (A/Tru X C57BL/6 Tru) 8-12 wk of age were used 
in these studies. Animals were supplied by the Trudeau  Institute Animal Breeding facility, 
Saranac Lake, NY, and were shown to be free of 11 common murine viruses according to tests 
by Microbiological Associates Viral Testing Service, Cockeysville, MD. Also, mice were found 
free of lactic dehydrogenase (LDH) virus as determined by the failure of an injection of AB6F1 
sera to raise the serum level of LDH enzyme in germ-free mice (14). Serum levels of LDH were 
measured with an LDH diagnostic kit (500)  from Sigma Chemical Co., St. Louis, MO. 
New Zealand white rabbits were originally purchased from Dutchland Laboratories, Denver, 
PA and have been randomly bred at the Trudeau Institute for a generation. Rabbit sera was 
used as a source of complement (C). 
Bacteria.  L.  monocytogenes (strain EGD, serotype 3b) was grown to log phase in Trypticase 
soy broth (BBL Microbiology Systems, Becton, Dickinson & Co., Cockeysville, MD), dispensed 
in 1.0-ml aliquots, and frozen at -70°C. An inoculum of bacteria was prepared for intravenous 
injection by diluting bacteria in saline and injecting 0.2 ml of the appropriate dilution. The 
standard inoeulum for intravenous immunization was 2 ×  10  a, and  10  was used for challenge 
in the studies on the passive transfer of immunity. 
Listeria Antigen.  The soluble Listeria antigen used in these studies was prepared according to 
published procedures (15).  Briefly, L.  monocytogenes was grown in  1,000  ml of low molecular 
weight Trypticase soy broth at 37°C with agitation for 72 h. The culture supernatant containing 
antigen was concentrated 10-fold by ultrafiltration on an Amicon XM-50 membrane (Amicon 
Corp.,  Scientific Sys.  Div.,  Lexington,  MA).  The  antigen  was  then  precipitated from  the 
concentrate by the addition of solid (NH4)2SO, to a final concentration of 75% saturation. The 
precipitate was resuspended in sterile HaO and dialyzed overnight against running tap H20. 
The antigen was sterilized by 0.45-/~M  millipore filtration, and  protein concentration deter- 
mined by the method of Lowry (16),  and lyophilized. The resulting antigen preparation was 
assessed as to its relative potency by its ability to elicit delayed-type hypersensitivity in  the 
footpads of 6-d Listeria-immune mice and  its failure to cause an  increase in footpad size of 
nonimmune animals. 
MuIFN  7 Induction in Spleen Cell Cultures.  Spleens were removed aseptically from groups of 
mice and placed in serum-free RPMI  1640 (Gibco Laboratories, Grand Island Biological Co., 
Grand Island, NY)  containing  10/~g/ml gentamycin. Cells were separated from  the spleen 
capsule by holding the spleen stationary and gently pressing out the cords of cells from the cut 
ends with a  glass rod. The cell cords were dispersed into a  single cell suspension by several 
cycles of aspiration with a pasteur pipette. The cells were washed two times with medium and 
counted in a  hemacytometer. Cell viability was always >95% as determined by exclusion of 
trypan blue. Spleen cells were suspended at a  concentration of 107 cells/ml and 2 ml of this 
suspension  was  placed  into  35  ×  22-mm  tissue  culture  dishes  (Costar,  Data  Packaging, 
Cambridge, MA), and IFN synthesis was induced by incubating the cultures with the designated 
concentration of mitogen for 24 h unless specified otherwise. 
Passive Transfer of Anti-Listeria  Immunity with  Spleen Cells.  Passive transfer of anti-Listeria 
immunity  was  measured  by  removing  spleens  from  control  or  Listeria-injected  mice  and 
preparing spleen cells as described in the preceding section, except that cells were suspended in 
RPMI  1640 supplemented with 1% fetal bovine sera (FBS) (Gibco Laboratories, Grand Island 
Biological Co.). The cell suspension was filtered through gauze, washed two times with medium, 
and then one spleen equivalent was injected intravenously into recipient mice as previously 
reported (17). 30 min before cell infusion, the recipients were injected intravenously with 105 L. 
monoeytogenes. The level of immunity transferred is expressed as the log~o protection, which was 
determined by subtracting the number of bacteria in the spleens of immune cell recipients from 
the number present in the spleens of normal cell recipients 48 h after injection of bacteria. 
Rabbit Anti-Mouse IgG Serum.  Rabbits were  immunized  by administering two  sequential 
intramuscular injections, 2 wk apart, of 200/xg of purified mouse IgG emulsified in complete 
Freund's adjuvant.  The  mouse  IgG was  purified by protein A-Sepharose  (Pharmacia  Fine 
Chemicals, Div. of Pharmacia Inc., Piscataway, N  J) affinity chromatography (18).  3 wk after 
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against whole mouse serum and purified IgG by immunoelectrophoresis. The rabbit anti-mouse 
IgG (hi(I) destroyed 50% of murine spleen cells in C-mediated lysis. 
Identification of MuarFNT-producing Cells.  The MulFNT-producing cells were tested for their 
susceptibility to C-mediated lysis after treatment with monoclonal antibodies directed against 
Thy-l.2, Lyt-l.2, Lyt-2.2, and I-A  k. The monoclonal anti-Thy-l.2 was originally produced by 
Marshak-Rothstein et  al.  (19) and  obtained from  the  Salk  Institute, La Jolla,  CA.  The 
anti-Lyt-1.2 and anti-Lyt-2.2 was purchased from New England Nuclear, Boston, MA. Anti-I- 
A  k antibody was produced from a hybridoma derived by Oi et al. (20) and obtained from the 
Salk Institute. Rabbit serum C was prescreened on thymocytes to determine lytic activity and 
was found at all dilutions tested to give <10% spontaneous lysis. Hybridomas secreting anti- 
Thy-l.2 antibody or anti-I-A  k were propagated in RPMI 1640 supplemented with 10% FBS. 
Supernatants from these cultures were used as a source of antibody at a 1:10 dilution. The anti- 
Lyt antibodies were used at a two- to fivefold excess of that required for lysis of the specific cell 
type in the preparation. 
Spleen cells from animals immunized 6 d earlier with L. monoqytogenes  were suspended at 5 
×  106 ceUs/ml in t.0 ml of RPMI  1640 containing 1% FBS and 10 #g/ml gentamycin. The 
desired  concentration of antibody was  added  to the  appropriate tubes and the suspension 
incubated in a 37°C water bath. 10 min later, C was added to a final dilution of 1:10. After a 
1-h incubation,  cells were washed free of antibody, and cell death was quantitated by exclusion 
of ethidium bromide (21). 
For the C-mediated cytolytic studies, a  modification of the procedure outlined above for 
induction of MuIFN  7 synthesis was used. The antibody-treated cells were distributed in 0.2-ml 
quantities to wells of a 96-well microtiter plate (Costar, Data Packaging). PHA was added to 
a final concentration of 5 #g/ml to each experimental group consisting of triplicate wells. After 
24 h  incubation, the supernatants from each well of the respective experimental group were 
pooled and assayed for IFN activity. 
Chemicals and Reagents.  Purified Con A (type IV) was purchased from Sigma Chemical Co., 
and purified PHA was  obtained from Burroughs Wellcome, Research Triangle Park,  NC. 
Staphylococcal enterotoxin A was produced by the Microbiology Biochemistry Branch, Division 
of Microbiology, Food and Drug Administration, Cincinnati, OH. Stock solutions (1 mg/ml) 
of the mitogens were prepared in sterile distilled H20. 
Cultures of L cells (strain Lpa) and pure bone marrow-derived macrophages were induced 
with either Newcastle disease  virus (NDV)  or polyinosinic-polycytidylic  acid  (poly [I]. poly 
[C]) according  to  published procedures  (22-24)  to  provide  preparations of MuIFNa  and 
MuIFNfl for use in these studies. 
IFN and Antiserum Neutralization Assays.  IFN assays were carried out as previously reported 
(25) using the L929B  strain of L  cells  and vesicular stomatitis virus as  the challenge virus. 
Because no MuIFNy standard is available, included in each assay was the MuIFN international 
standard (G-002-904-511),  and all titers were corrected against this international standard. 
The antiserum neutralization assays of antiviral activities were done as described by Havell 
et al. (26) also using L929B cells and vesicular stomatitis virus. The anti-L cell MuIFN serum 
used was  the  kind gift  of Dr.  Erwin Braude and Dr.  W.  E.  Stewart  II  (Memorial Sloan- 
Kettering Cancer Center, NY). This antiserum, which neutralizes both MuIFNa and MuIFN/~, 
was  raised in a  goat by immunization with NDV-induced L cell  IFN (specific activity,  106 
U/mg)  known to  possess both  MuIFNa and MuIFN/~ activity  (27,  28).  The rabbit anti- 
MuIFN  7 neutralizing serum was the kind gift of Dr. Juana Wietzerbin (Curie Institute, Paris, 
France). This antiserum was raised according to published procedures (29). 
Molecular Weight and Isoelectric Point Determinations.  Molecular weight determinations were 
carried out by means of gel filtration column chromatography using Bio-Gel P-60,  100-200 
mesh (Bio-Rad Laboratories, Richmond, CA) as the column matrix. The column buffer was 
0.05  M  Na citrate with 1 M  NaCI, pH 6.0. The column (73 ×  2.5 cm) was run at 4°C and 
calibrated with  the  following molecular weight  markers:  rabbit  IgG,  150,000;  ovalbumin, 
43,000; myoglob[n, 18,500; and cytochrome C, 12,000.1-ml fractions were collected at a column 
flow rate of 15 ml/h. 
Chromatofocusing, a technique originally described by Sluyterman et al. (30, 31), was used 
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containing the ion exchanger PBE 94 as well as the polybuffer exchangers, polybuffers 96 and 
polybuffer  74,  were  purchased  from  Pharmacia  Fine  Chemicals,  Div.  of Pharmacia,  Inc. 
Samples and  the ion exchanger PBE 94 were equilibrated  in starting buffer (0.025  M  Tris- 
acetate, pH 8.4),  and the column was packed (14 ×  0.5 cm) with PBE 94. The sample to be 
chromatofocused was then run into the column bed, and the generation ofa pH gradient (5.0- 
8.0) was achieved by elution with the polybuffer system (3% polybuffer 96 and 7% polybuffer 
74, adjusted to pH 5.0 with acetic acid). The column was run at room temperature with a flow 
rate of 15 ml/h.  1-ml fractions were collected and assayed for IFN activity, and the pH of each 
sample measured at room temperature. 
Results 
Enhanced  IFN Production  by  Spleen  Cells from  Listeria-immune  Mice.  Because  T  cell 
mitogens are inducers of IFNy in nonimmune animals  (10,  11), it was considered of 
interest  to determine  the relative  ability of spleen  cells obtained  from mice actively 
expressing  T  cell-mediated  antibacterial  immunity  to produce  IFN in  response  to 
polyclonal  T  cell  activators.  Spleen  cells  from  both  control  and  mice  infected 
intravenously  6  d  earlier  with  Listeria  were incubated  for 24 h  with  the  designated 
concentrations  of the  mitogenic agents  (Table  I).  The results  of these studies  show 
that spleen cells from Listeria-immune animals produced levels of IFN at least  16-fold 
higher  than  similarly  treated  cultures  from  nonimmune  mice.  It  was  repeatedly 
observed  in  20 separate  experiments  that  spleen  cell  cultures  from Listeria-immune 
mice produced  10-20 times  more antiviral  activity than  normal  cells induced  with 
Con A  or PHA, although the absolute IFN units fluctuated two- to fourfold between 
experiments.  Specific antigenic stimulation of spleen cells from Listeria-immune  mice 
with a  preparation of soluble Listeria antigen(s)  resulted in the synthesis of low levels 
of IFN,  but  the  antigen  failed  to  elicit  IFN  in  nonimmune  spleen  cell  cultures. 
Marginal  levels  of IFN  activity  (<---2) were  detected  in  supernatants  from  Listeria- 
immune spleen cell cultures not incubated with the mitogens. 
Characterization  of Immune Spleen Cell IFN.  The y class of interferons is characterized 
as  being  inactivated  at  low  pH  (2.0)  and  by  the  failure  of antisera  raised  against 
IFNa and IFN~ to neutralize  its antiviral  activity (32, 33).  In the following studies, 
TA~L~  I 
MuIFNy Production after Mitogenic or Antigenic Stimulation of Spleen Cells 
from Normal or Listeria-immune Mice 
Spleen cell  Mitogenic agent*  24-h IFN titer 
source 
Control mice  PHA (5 #g/ml) 
Con A (1/~g/ml) 
Listeria antigen 
(5 #g/ml) 
None 
+6-D Listeria-  PHA (5 #g/ml) 
immune mice  Con A (1 #g/ml) 
Listerm antigen 
(5/~g/ml) 
None 
U/ml 
256 
64 
<2 
<2 
4,096 
3,072 
32 
with the  * 2-ml cultures of spleen cells (107 cells/ml) were incubated for 24 h 
designated final concentrations of mitogenie agents. 
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the IFN produced by Listeria-immune  spleen cell cultures stimulated with Con A or 
PHA were analyzed as to their stabilities at pH 2.0 and to their antigenic properties. 
Murine IFN preparations containing both MuIFNa and MuIFNfl were included as 
controls in these experiments. These MuIFN were produced by L  cells and by pure 
cultures of macrophages induced with NDV or poly (I). poly (C) (22-24). All samples 
were dialyzed at  4°C  against  a  pH  2.0 buffer for 5  d  and  returned to pH  7.4 by 
dialysis against PBS. The results in Table II show that acidification of the L cell and 
macrophage IFN preparations resulted in no more than a twofold decrease in antiviral 
activities, whereas the mitogen-induced spleen cell IFN were found to be relatively 
more  acid  labile.  In  repeated  pH  2.0  lability  studies,  it  was  observed  that  each 
MuIFN), preparation produced in vitro possesses  a  fraction (3-15% of the original 
activity) that was not inactivated by the 5-d acid treatment. 
The antigenic classification of the IFN preparations used in the pH stability studies 
was  done through  the use of specific anti-MuIFN sera. A  goat anti-MuIFN serum 
possessing both anti-MuIFNa and anti-MuIFNfl activity and a rabbit anti-MuIFNy 
serum were used to determine the degrees to which the antiviral activities of each test 
IFN could be neutralized (Table II). The antiserum possessing specific populations of 
antibodies directed against MuIFNa and MuIFNfl exhibited very high neutralizing 
titers for the macrophage and L cell IFN but failed to inhibit the antiviral activities 
of either the PHA or Con A-induced spleen IFN preparations. Conversely, the rabbit 
anti-MuIFN't serum neutralized only the mitogen-induced spleen cell IFN.  Similar 
neutralization studies  performed with the acid-stable portion of the  PHA-indueed 
spleen cell IFN showed that  it also was IFNy by its antigenic properties (data not 
shown). Thus, based on the relative acid lability and the serological results, the major 
IFN activity produced by the spleen cell cultures was MuIFNy. However, it should be 
mentioned that, whereas the major antiviral activity in these preparations is MuIFNT, 
we cannot exclusively eliminate the possible presence of low levels of other antigenic 
TABLe  II 
Properties of Different MulFN Preparations 
Source of MulFN  Inducing agent 
Neutralizing titer 
pH 2.0 treatment*  of~: 
Before  After 
Anti-  Anti- 
MulFN  Mu- 
(~ + B)§  IFN~, 
Lpa cells  NDV  12,288  8,192  14,746  <12 
poly(I) • poly(C)  3,072  1,536  52,428  < 12 
Bone marrow macrophages  NDV  4,096  2,048  6,554  <12 
poly(I) • poly(C)  512  512  39,322  <12 
Listeria-immune  spleen  cell  PHA  1,024  32  <32  50 
cultures  Con A  384  64  <32  50 
* Samples dialyzed at 4°C for 5 d against Clark Lubs pH 2.0 KCI-HCI buffer, followed by dialysis for I d 
against PBS, pH 7.4. 
4: The antiserum neutralizing titer is expressed as the reciprocal of the highest dilution of antiserum that 
when mixed with an equal volume of test IFN (20 U/ml) neutralizes 50% of the antiviral activity of the 
IFN. 
§ Antiserum possessing anti-MuIFNy and anti-MuIFNfl neutralizing antibodies. E. A. HAVELL, G. L. SPITALNY, AND P. J. PATEL  117 
classes of MulFN. In the antibody neutralization studies, a final concentration of 10 
U/ml of antiviral activity is reacted, and if<10% of the activity (<1 unit) is mediated 
by an IFN molecule not neutralized by the antibody, its antiviral activity would not 
be detected in this neutralization assay (34). 
Temporal Relationship between the  Development of Anti-Listeria  Immunity and Enhanced 
Capacity of Spleen Cells to Produce MuIFNy.  The following experiments were designed 
to  determine whether  the  enhanced  production  of MuIFNy by spleen  cells  from 
Listeria-immune mice coincided with the peak of the antibacterial-immune response. 
This was tested by measuring the capacity of spleen cells harvested against time of 
Listeria infection'to produce PHA-induced MuIFNy and to passively transfer antibac- 
terial immunity to normal recipients. The results illustrated in Fig. 1 clearly demon- 
strate a parallel between the development of antibacterial immunity and the ability 
of spleen cells to produce high-titered MuIFNy. Thus, the ability of spleen cells to 
produce  MuIFNy  and  to  transfer  protective  immunity  developed,  peaked,  and 
declined at the same times. 
Cellular Origin of MuIFNy.  Evidence indicates that T  cells are the major producers 
of lymphokines, although B cells have also been implicated as potential contributors 
of these soluble mediators (35,  36).  In the following studies, monoclonal antibodies 
and C were used to determine the nature of the spleen cells producing MuIFNy. The 
findings presented in Table III reveal that treatment of cells with anti-Thy-l.2 plus 
C virtually abolished production of MuIFNy. It should be noted that the low level of 
IFN activity that was produced after anti-Thy-1.2 plus C treatment was identified as 
MuIFNy by its lability at pH 2.0 and by its antigenic properties (results not shown). 
The  synthesis of this  residual  MuIFNy could conceivably by attributed  to  small 
numbers ofT cells possessing little or no Thy-1 antigen (37). in contrast to the almost 
total elimination of MuIFNy production by anti-Thy-l.2, destruction of B lympho- 
512 
t  ,~  (0  12  14  1"6 
nAyS  OF LIST[RiA  INF[CTION 
FIo.  1.  Development of anti-Listeria  immunity and the capacity for enhanced MuIFNy synthesis 
by spleen cells from Listeria-infected  mice. At the indicated day after intravenous injection of 2 x 
10  a L. monoqtogenes, pooled spleen cells from groups of five mice were either induced with 5 #g/ml 
of PHA for 24 h  to determine their ability to produce MuIFNy  (line graph)  or tested for their 
ability to adoptively transfer anti-Listeria  immunity (bar graph). 118  ENHANCED  MURINE INTERFERON  y  PRODUCTION 
TABLE III 
T Cell Dependence of MulFNy Synthesis in Spleen Cultures  from Mice Immunized with Listeria 
Monocytogenes 
Spleen source  Spleen cell treatment*  24-h IFN yield 
U/ml 
Nonimmune control mice  None  16 
6-d L&term-immune mice  None  2,048 
6-d Listeria-immune mice  Antibodies -  C (separate  1,024 
groups treated with 
either anti-Thy-  1.2, 
anti-I-A  k, or anti-IgG) 
6-d Listeria-immune mice  C  1,024 
6-d Listeria-immune mice  Anti-Thy-1.2 +  C  32 
6-d Listeria-immune mice  Anti-I-A  k +  C  2,048 
6-d Listeria-immune mice  Anti-IgG +  C  2,048 
6-d Listeria-immune mice  Anti-Thy-l.2 +  I-A  k +  C  16 
* Spleen cells were suspended at 5 ×  l0  s cells/ml in 1.0 ml of RPMI 1640 supplemented with 1% FBS and 
10 ~g/ml gentamycin. Antibody and C were added to the designated experimental groups. 
After antibody treatment, all cells were induced with PHA (5/~g/ml). 
TABLE  IV 
Lyt Phenotype of MulFNy-producing T Cells 
Spleen source  Spleen cell treatment*  24-h IFN yield 
Nonimmune control mice 
6-d L,)teria-immune mice 
6-d Lister,a-immune mice 
6-d Listeria-immune mice 
6-d Listeria-immune mice 
6-d Listeria-immune mice 
6-d Listena-immune mice 
6-d Listena-immune mice 
6-d Listeria-immune mice 
6-d Listen'a-immune mice 
6-d Listeria-immune mice 
None 
None 
Antibody  -  C  (separate  groups 
treated with either 
anti-Thy-  1.2, anti-Lyt-  1.2, or 
anti-Lyt-2.2) 
C 
Anti-Thy-l.2 + C 
Anti-Lyt-l.2 + C 
Anti-Lyt-2.2  +  C 
Anti-Lyt-l.2 +  Lyt-2.2 +  C 
Anti-Lyt-l.2 + anti-Lyt-l.2 +  C~ 
Anti-Lyt-2.2  + anti-Lyt-2.2  +  C~ 
Recombination of anti-Lyt-l.2 + 
C-treated cells with anti-Lyt-2.2 
+ C-treated cells. 
U/ml 
16 
2,048 
2,048 
1,024 
32 
64 
384 
16 
96 
512 
1,024 
* Spleen cells suspended at 5 ×  l0  s cells/ml in 1.0 ml of RPMI 1640 supplemented with 1.0% FBS and I0 
#g/ml gentamycin. Antibody plus C was added to the appropriate groups as described in Materials and 
Methods. After antibody treatment, all groups were induced with PHA (5 p,g/ml). 
After antibody plus C treatment, viable cells were determined by exlusion of ethidium bromide, and the 
number of viable cells was then adjusted to 5 X 10  s cells/ml before the addition of PHA. 
cytes with anti-IgG plus C  or anti-I-A plus C  had no detectable effect on the titer of 
PHA-induced  MuIFNy. 
Similar studies were performed to identify the T  cell subpopulation(s)  producing 
MuIFNy  through the use of specific cytolytic monoclonal antibodies directed against 
Lyt  differentiation antigens.  In  Table  IV,  it  is  shown  that  the  T  cells  producing 
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Lyt-2.2  and  C.  The  combined  effects of the  two  anti-Lyt  antibodies  reduced  by 
MuIFNy titer to slightly below that of the anti-Thy-l.2 plus C-treated cells. 
Reduced MuIFN  7  titers were also observed when cells treated with anti-Lyt-l.2 
plus C were restored to the original number per culture (5 ×  10  e cells/ml). Based on 
this  observation,  it  is  reasonable  to  conclude  that  the  T  cell  subpopulations  not 
destroyed by anti-Lyt-l.2 plus C  are not the contributors of the major portion of the 
MuIFNy activity. This finding does not  rule out the possibility that  for maximum 
MuIFNy production, Lyt-l+2  -  cells might have to interact with other cell popula- 
tion(s). This is based on the additional findings presented in Table IV, which show 
that  almost  maximum  MuIFN  7  titers  were  obtained  by  (a)  restoring  the  cells 
remaining after anti-Lyt-2.2 plus  C  treatment  to  the original  number of cells per 
culture  (5  X  106 cells/ml)  or (b)  by combining cells surviving after treatment with 
anti-Lyt-l.2 with those surviving after treatment with anti-Lyt-2.2 plus C. However, 
the  increase  in  titers  in  each  of the  above  cases  might  be  on  the  borderline  of 
significance because the MuIFN  7 titer after anti-Lyt-2.2 plus C  treatment was only 
threefold (384) lower than C-treated controls (1,024). Thus, this difference falls close 
to the inherent twofold error of the interferon assay. 
Kinetics of MuIFNy Release.  The  kinetics  of MuIFN7  release  from  6-d  Listeria- 
immune spleen cell cultures stimulated with either 5/~g/ml of PHA or  1 ~g/ml of 
Con  A  are presented in  Fig.  2.  Similar patterns of IFN release were exhibited by 
cultures induced with either T  cell mitogen.  IFN was  first detected in  the culture 
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Fic.  2.  Kinetics of MulFN-/ release from spleen cell cultures.  Replicate cultures of 6-d Listeria- 
immune spleen cells  (10  7 cells/ml)  were incubated with  PHA  (5  #g/ml)  or Con  A  (1  #g/ml). 
Supernatants of duplicate cultures from each mitogen-treated group were collected at  the times 
indicated, pooled, and centrifuged. The supernatants were stored at 4°C until they were assayed for 
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supernants as early as 4 h after the addition of the mitogens, with peak levels occurring 
at  18 h.  After this time, MuIFNy levels remained constant  for an additional 48 h. 
From the slopes of the production curves and the levels of IFN released, it is concluded 
that the rate of synthesis and quantities of MuIFNy produced by cultures of Listeria- 
immune spleen cells was the same when PHA or Con A were used as inducers. The 
kinetics  of MuIFNy  release  are  similar  to  those  reported  for  alloantigen-induced 
MuIFN~, (38). 
MuIFNy Induction by Different Concentrations of T Cell Mitogens.  A series of studies was 
carried out to establish  the optimum concentrations of T  cell mitogens required to 
induce  the  maximum  synthesis  of MuIFNy  in  spleen  cell  cultures  from  Listeria- 
immune and control mice. In addition to Con A and PHA, staphylococcal enterotoxin 
A  (SEA)was  included in these studies because it has been reported to be a  potent 
inducer  of IFNy  in  both  murine  and  human  cell  systems  (11,  39).  The  findings 
presented in Table V  reveal that the MuIFNy levels from the Listeria-immune spleen 
ceils were at least 10-fold greater than the corresponding yields from similarly treated 
nonimmune  control  cells.  MuIFNy  production  plateaued  in  immune  spleen  cell 
cultures incubated with PHA concentrations in the range of 0.5-10 #g/ml, whereas 
Con A  elicited the highest  titers of MuIFNy activity in  both control and  immune 
cultures  at  a  concentration  of  1 /.tg/ml.  The  SEA  failed  to  induce  MuIFNy  in 
nonimmune control cultures with any of the concentrations tested. In fact, SEA was 
only effective in inducing MuIFNy in immune spleen cell cultures, with the highest 
level  of antiviral  activity  being  detected  in  cultures  incubated  with  the  highest 
concentration (I0 #g/ml) of SEA tested. 
The diterpene ester 12-O-tetradecanoylphorbol-13-acetate (TPA) and the structur- 
ally related compound-mezerein have been reported  (40)  to enhance the  levels of 
human  IFNy (HuIFNy) produced by primary cultures of human  leukocytes stimu- 
lated by PHA or several other T cell mitogens. Therefore, experiments were performed 
to determine whether these esters might also further augment the yield of MuIFNy 
produced by Listeria-immune spleen cells. In these studies, cultures of spleen cells from 
immune mice were incubated with different concentrations of TPA or mezerein 3 h 
before the addition of PHA (5 #g/ml). Little or no enhancement in interferon yields 
TABLE  V 
MulFNy Production by Normal and Listeria-immune Spleen Cell Cultures Induced with Different 
Concentrations of T Cell Mitogens 
Source of spleen cells  Mitogen 
24-h IFN yield (U/ml) induced by mitogen concentrations 
(t~g/mt) 
0.05  0.1  0.5  i  5  10 
Control  PHA  ND*  <4  16  32  128  128 
Listeria immune*  PHA  ND  80  1,024  1,024  1,024  1,536 
Control  Con A  <4  <4  8  32  <4  <4 
Listeria immune*  Con A  <4  4  256  768  384  32 
Control  SEA  <8  <8  <8  <8  <8  <8 
Listeria immune*  SEA  <8  24  48  32  128  192 
* Spleen cell cultures obtained from mice injected intravenously 6 d  before with 2 X  103 L. monocytogenes. 
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FIG. 3.  Molecular weight estimation of MulFN~, by  Bio-gel P-60 filtration  chromatography. 
Column buffer was 0.05 M Na citrate with 1 M NaCI, pH 6.0. Column dimensions and conditions 
for elution are given  in Materials and Methods. Interferon activities (0) were determined on each 
1-ml fraction. Column void volume was determined by exclusion  of rabbit IgG, and calibration was 
done with the following markers (X): ovalbumin, 43,000; myoglobin, 18,500; and cytochrome C, 
12,000. 
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FIc. 4.  Isoelectric point  determination  of MuIFNy  by chromatofocusing. 1 ml  of MuIFNT, 
equilibrated in starting column buffer (0.025 M Tris-acetate, pH 8.4), was applied to the chroma- 
tofocusing column. Conditions of elution and generation of the pH gradient are as presented in 
Materials and Methods. 1-ml fractions were assayed for antiviral activity, and the pH of each 
fraction was determined at room temperature. The MulFNy unitage applied was 1,536 units, and 
the total units recovered was 484. 
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was observed in the cultures pretreated with either agent in the concentration ranges 
(1-50 T/g/ml) reported by others to enhance HuIFN7 levels (results not shown). 
Molecular Weight of  MuIFNy.  The availability  ofhigh-titered MuIFN7 preparations 
produced by PHA-induced Listeria-immune spleen cells has enabled the analysis of 
certain of its physicochemical properties. Molecular weight determinations  were made 
by gel filtration chromatography using Bio-Gel P-60 under nondenaturing  conditions. 
It would have been preferable to estimate the molecular weight of MuIFNy by sodium 
dodeeyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), however, treatment 122  ENHANCED  MURINE  INTERFERON  y  PRODUCTION 
of MuIFNT with SDS (0.1 or 1%) under both reducing and nonreducing conditions 
performed at a  number of temperatures consistently resulted in substantial losses of 
antiviral activity. Treatment of HuIFNT with this anionic detergent has also been 
reported to cause a ~90% loss in HuIFNT antiviral activity (41). The elution profile 
of MuIFNT  from  the  Bio-Gel  P-60  column  is  presented  in  Fig.  3.  The  MuIFNT 
activity has an estimated 38,000  +  4,000 tool wt, and the recovery of antiviral activity 
was in the order of 50% of the applied unitage. 
Isoelectric Point of MuIFNy.  The isoelectric point of MuIFNy was determined by 
chromatofocusing (30, 31).  Preliminary isoelectric focusing studies using ampholytes 
to  generate a  pH  gradient  in  acrylamide gels revealed that,  unlike MulFNa  and 
MuIFN/~ (42),  the MuIFN  T focused in the acidic region of the gradient. Therefore, 
the polybuffer system used to develop a  pH gradient during chromatofocusing was 
adjusted to generate a linear pH gradient between pH 5.0-8.0. The resulting elution 
profile of MuIFNT activity from the chromatofocusing column is presented in Fig. 4. 
Greater than 90%  of the recovered MuIFN  T focused between pH  5.0-7.0,  and the 
MulFN  T is shown to exhibit considerable molecular charge heterogeneity. A major 
peak  of MuIFN  T  activity focused between  pH  5.0-5.6,  with  a  second  extremely 
disperse region of activity from pH 5.8-7.0. 
Discussion 
The studies presented in this paper show that T  lymphocytes from the spleens of 
animals  with  an  ongoing T  cell-mediated  immune  response  to  Listeria  infection 
acquire the ability to produce significantly more MuIFN  T than splenic T  cells from 
uninfected mice.  In  addition, it was revealed that  the ability of spleen  cells from 
immune mice to produce high-titered MuIFNT developed and declined eoncordantly 
with the production and loss of T  cells capable of passively transferring anti-Listeria 
immunity. Prior studies have shown that a  number of other parameters of cellular 
activity associated with an onging cell-mediated anti-Listeria  response display similar 
kinetics  of generation  and  decay.  These  include  spleen  cell  proliferation,  spleen 
cellularity, delayed sensitivity to Listeria antigens  (17),  and macrophage activation 
(43). Our results indicate that during the generation of anti-Listeria  immunity, there 
is  an  enlargement of a  T  cell  subpopulation  capable  of producing  MuIFN  7.  An 
alternative explanation is that the T  cells in the normal spleen that are capable of 
producing low titers of MuIFNy are individually activated to produce more IFN as 
a result of infection. Although we have only quantitated the enhancement of MuIFN  T 
synthesis by spleen cells stimulated with T  cell mitogens during the generation of 
antibacterial immunity, it would be of interest to determine whether the production 
of other mitogen-induced lymphokines is also enhanced. 
The T cell origin of MuIFNT was established by showing that treatment with anti- 
Thy-l.2 plus C  greatly dimishishes the production of this lymphokine. In contrast, 
treatment of cells with anti-I-A or anti-IgG to destroy B cells did not inhibit MuIFNy 
synthesis. The MuIFNy-secreting T  cells were relatively susceptible to C-mediated 
lysis with anti-Lyt-l.2, which reduced the MuIFNT titer to nearly the same level as 
treatment with anti-Thy-l.2. This is not surprising because published studies have 
shown that virtually all T  cells outside the thymus display Lyt-1 antigens on their 
surface, though not all are susceptible to C-mediated lysis (37). Treatment of spleen 
cells with anti-Lyt-2.2 +  C, on  the other  hand, only slightly reduced the titer of E. A.  HAVELL, G. L. SPITALNY, AND P. J.  PATEL  123 
MulFNy. If the MulFNy-secreting lymphocytes displayed Lyt-1+2  +, then they should 
be equally susceptible to destruction by either anti-Lyt-1 or anti-Lyt-2. Therefore, 
there can be little doubt that  the Lyt-l+2  -  T  lymphocyte is  the main  producer of 
MuIFNy in this system. A small contribution by Lyt-1-2  + T  cells must be considered, 
however, even though the reduced production caused by anti-Lyt-1-2  + antibody is 
close to the limitations of the inherent twofold error of the IFN assay. These findings 
are in contrast to an earlier publication (44) that reported that an Lyt- 1-2  + T cell was 
the major source of MuIFNy in animals immunized with Calmette-Guerin bacillus 
and  challenged  with  specific  antigen.  These  authors  also  reported  the  MuIFNy- 
producing cell was destroyed by anti-Ia and anti-IgG. It might be significant that T 
cells within  the  Lyt-l+2  -  population  are  known  to  secrete interleukin  2  and  that 
interleukin 2 is generated without participation of other T  cells (45). 
The criterion most widely used to differentiate IFNT from other IFN is its loss of 
antiviral activity after acidification. It has been repeatedly observed that MuIFNy is 
relatively  more  labile  at  pH  2.0  than  other  MuIFN.  However,  we  have  always 
detected a variable fraction (3-15% of the total pre-acidified unitage) within MuIFNy 
preparations that  remains active after 5 d  pH 2.0 treatment.  Similar findings were 
reported by Wietzerbin et al. (46). A potent rabbit antiserum raised against a partially 
purified  MuIFNy  (5  Z  10  ~ U/mg  protein)  neutralized  the  acid-stable  MuIFNy 
component, whereas a neutralizing antiserum possessing specificity for both MuIFNa 
and MuIFNfl did not neutralize this activity. Thus, based on this serological analysis, 
it is possible that not all MuIFNy molecules are acid labile. The heterogeneity of the 
MuIFNT  molecules  in  the  PHA-induced  preparations  is  evidenced  by  additional 
findings  in  this  paper.  For example,  isoelectric point  determinations  by means  of 
chromatofocusing revealed that the MuIFNy molecules are primarily acidic proteins 
focusing in a broad pH range from 5.0-7.0. Addtional studies (E. A. Havell and G. L. 
Spitalny, manuscript submitted for publication) have shown that MuIFNy antiviral 
activity  focusing between  pH  5.0  and  5.6  binds  specifically to  a  Con  A  affinity 
column, which indicates its glycoprotein nature. Molecular weight determinations by 
means of gel filtration chromatography on Bio-gel P-60 revealed the molecular weight 
of MuIFNT to be 38,000 __. 4,000.  Studies by others have established the molecular 
weight  of other  murine  lymphokines  to  be  within  a  similar  size  range  (47,  48). 
However, because our molecular weight studies were carried out under nondenaturing 
conditions, we cannot rule out the possibility of complexes of low molecular weight 
MuIFNT  yielding an  apparent  38,000  mol  wt  under  the  conditions  used  for  the 
molecular weight estimations. With regard to this last point, Yip et al. (48) originally 
reported that the molecular weight of HuIFNT estimated by gel filtration chromatog- 
raphy  to  be  58,000,  but  later  found  (41)  that  the  remaining  activity  after  SDS 
treatment could be resolved by SDS-PAGE into 25,000- and 20,000-mol wt compo- 
nents.  This suggests the molecular aggregates cause the apparent  higher molecular 
weight forms observed under nondenaturing conditions. The molecular diversity of 
MuIFNT could conceivably result from a variety of factors that have been shown to 
be responsible for the molecular heterogeneity within other IFN preparations. These 
include (a) distinct IFN gene classes and their differential induction in different cell 
types  (50,  51),  (b)  multigene IFN  families within  antigenically distinct  IFN classes 
(52),  and  (c)  microheterogeneity caused  by  differing degrees  of post-translational 
processing, such as in the glycosylation of IFN proteins (53, 54). 124  ENHANCED MURINE INTERFERON y PRODUCTION 
The exact role, if any, played by MuIFNy in the regulation of immunity is still a 
matter of conjecture. Although there is no direct evidence for a function of MuIFNy 
in anti-Listeria  immunity, the parallel development of T  cells that exhibit enhanced 
production of MuIFNy and ofT cells that mediate immunity is perhaps suggestive of 
an important role for MuIFNy in cell-mediated immunity in general. The elucidation 
of the possible functional role(s) of MuIFNy in immunity will be made more difficult 
in view of the fact that distinct molecular populations of MuIFNy are produced by 
T  cells. 
Summary 
Spleen cell cultures derived from animals infected 6 d  earlier with Listeria monocy- 
togenes produced  10-20-fold more murine  interferon y  (MuIFNy)  than spleen cells 
from nonimmune mice in response to stimulation with T  cell mitogens. A  striking 
temporal association was found between the enhanced synthesis of MuIFNy and the 
development  of anti-Listeria  immunity  in  that  both  the  potential  for  increased 
MuIFNy production and the generation of Listeria-protective  T  cells developed and 
then decayed in unison. Treatment of spleen cells with monoclonal anti-Thy-l.2 plus 
complement  virtually  abolished  the  ability  of cells  from  Listeria-immune  mice  to 
synthesize MuIFNy. The T cells producing MuIFNy were found to be more susceptible 
to complement-mediated lysis with monoclonal anti-Lyt-l.2 than with monoclonal 
anti-Lyt-2.2. The production of MuIFNy was  not  affected by treating spleen cells 
with anti-IgG antisera or with a monoclonal antibody directed against I-A specificities. 
MulFN,/was detected 4 h after the beginning of mitogenic stimulation of spleen cell 
cultures, and peak levels of MuIFNT were reached by 18 h. The IFN synthesized by 
mitogen-induced spleen cells derived from Listeria-immune mice were relatively labile 
at pH 2.0 and neutralized by a rabbit anti-MuIFNy serum but not by an antiserum 
having specificities for MuIFNa and MuIFNfl. The apparent molecular weight of the 
MuIFNy, as estimated by molecular sieving on a Bio-gel P-60 column, was estimated 
to  be  38,000,  and  the  isoelectric  point  as  determined  by  chromatofocusing  was 
extremely heterogeneous, ranging between pH 5.0 and pH 7.0. 
The authors would  like to acknowledge  the excellent technical assistance of Donald Auclair 
and Bruce Rankin. 
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